Persisting meningoencephalitis, usually fatal, has been described previously in patients with hypogammaglobulinaemia. This disorder has occurred most often in sex linked agammaglobulinaemia, and has commonly been due to infection with echoviruses. Other enteroviruses cause similar infections in sex linked agammaglobulinaemia, however, and vaccine associated poliomyelitis' 2 and Coxsackie B3 meningoencephalitis3 have been described. In contrast, persisting meningoencephalitis is rare in late onset primary hypogammaglobulinaemia, although fatal measles encephalitis has been reported in an adult with this condition,4 and one patient with late onset hypogammaglobulinaemia died of meningoencephalitis due to infection with echovirus 11.5
Standard intramuscular immunoglobulin replacement treatment has not prevented the development of meningoencephalitis. In Failure of intraventricular gammaglobulin and a interferon for persistent encephalitis 949 were 59%. There was no family history of affected males among maternal relatives.
Treatment with intravenous immunoglobulin was started at the time of diagnosis and he received 4-5 ml/kg of a 6% preparation (240-300 mg/kg) (Commonwealth Serum Laboratories) at intervals of four weeks. He remained in excellent health during the next five years. The median serum IgG concentration immediately before immunoglobulin infusions during his eighth year of life was 2-78 g/l.
At 81/2 years of age he had an illness during which he had vomiting and occasional headaches for 10 days. At 9 years his mother noted a slight mood change; at 91/2 years he developed horizontal nystagmus. Cerebrospinal fluid was examined and showed a raised protein concentration and a mild leucocytosis. A picornavirus was isolated on culture of the cerebrospinal fluid but was not detected in faeces.
The nystagmus persisted and he developed bilateral sensorineural deafness necessitating the use of hearing aids. Psychometric assessments showed defects in short term auditory memory, a discrepancy between verbal and performance scores by the Wechsler Intelligence Scale for Children, and reduced immediate visual memory. At 10 years of age he developed spontaneous bilateral subdural effusions which were drained.
After viral isolation from the initial sample of cerebrospinal fluid at 91/2 years, he started high dose intravenous immunoglobulin treatment (figure). For 22 months he received 200 ml of intravenous immunoglobulin two times a week (1 g/kg/week). The immunoglobulin used had neutralising antibody activity against 30 TCD50 (30 times the tissue culture dilution 50% end point) of the virus ranging from 1:8 to 1:32.
Serum from family members was tested against his viral isolates and his father's serum was shown to have a neutralising titre of 1:32. Plasma was obtained from his father on two occasions by plasmapheresis, and the patient received 100 ml of plasma by intravenous infusion each week for two five week treatment periods. Transfer factor was prepared from his father's lymphocytes and was given weekly in conjunction with the plasma infusions.
Virus was not recovered from lumbar samples of cerebrospinal fluid taken during the six months after initial viral isolation, but was detected again in it three weeks after his last plasma infusion. Serum from 300 blood donors chosen at random was screened for neutralising antibodies to the virus isolated. The 11 donors with titres of >1:16 had plasmapheresis performed. An IgG preparation manufactured from this plasma pool was given into his left lateral cerebral ventricle through a Rickham reservoir. The IgG had neutralising antibody activ- '.' Failure of intraventricular gammaglobulin and a interferon for persistent encephalitis 951 Recently Erlendsson et al reported their treatment of a boy with X linked hypogammaglobulinaemia with meningoencephalitis from whom echovirus type 5 was isolated at the age of 3 years.8 He failed to respond to intravenous immunoglobulin with a titre of antibody to echovirus 5 of 1:32 given at weekly intervals, but when 138 mg of immunoglobulin was given directly into his cerebral ventricles over five days the virus could not be cultured for two months. After reappearance of the virus in his cerebrospinal fluid he received a further 5 6 g of intraventricular immunoglobulin and he has remained well. The same report described a 12 year old girl with echovirus 25 encephalitis treated in similar fashion who had not had virus cultured from her cerebrospinal fluid during the next 16 months.
There have been several reports of unsuccessful treatment with specific antibodies and with intraventricular immunoglobulin. Plasma infusions containing specific antibody have been unsuccessful or only partly successful in at least four patientsl1-13;
hyperimmune sheep serum with antibod2 to echovirus 3 failed to eradicate the virus1; and intraventricular immunoglobulin treatment was unsuccessful in two patients.5 15 In one of the patients failing to respond to intraventricular immunoglobulin, the virus was no longer isolated from ventricular fluid after treatment but treatment had no effect on the patient's progressive course. 5 The second patient received a total of 12.6 g of Sandoglobulin in two courses of intraventricular treatment, but echovirus 11 continued to be isolated from the cerebrospinal fluid.
The patient described in this report received a total of 38 15 g of intraventricular immunoglobulin in four courses of treatment, 1 g being given daily for 21 consecutive days on one occasion. The immunoglobulin administered came from two geographically different donor pools, and on each occasion virus recovery from cerebrospinal fluid stopped during administration but recurred within weeks of stopping the treatment. He had also received 2500 g of intravenous immunoglobulin during 22 months of treatment, without apparent effect on the clinical course of his meningoencephalitis. Thus even extremely high dose treatment with immunoglobulin preparations may be unsuccessful in this condition.
Exogenous interferon may be expected to be beneficial in chronic viral disorders by limiting cellular viral replication and preventing infection of uninfected cells. In addition, recombinant human leucocyte interferon has been shown to augment natural killer cell activity as well as antibody dependent cellular cytotoxicity and monocyte cytotoxicity.16 17 Systemically administered interferon is prevented by the blood-cerebrospinal fluid barrier from reaching the central nervous system.18 Several investigators have given interferon intrathecally to small numbers of patients with neonatal herpes, multiple sclerosis, or intracranial malignancies, either by the lumbar route19 20 or by an intraventricular reservoir.18 Adminstration has in general been well tolerated, although without specific success in the disorders treated. The use of intrathecal interferon in the treatment of meningoencephalitis associated with hypogammaglobulinaemia has not been reported previously.
The patient reported here received a total of 121x 10 units of recombinant a interferon in three courses. An initial subcutaneous test dose of 5000 units was given without apparent adverse reaction; this was followed by intraventricular test doses of 2500 units, 25 000 units, and 250 000 units. During the first course of treatment the interferon was increased to 2x 106 units three times weekly; during the-third course he received 3x 106 units daily into the cerebral ventricles for 16 days. The only side effect noted was progressively increasing drowsiness during each course of treatment, which resolved within one or two days of its completion.
As with the intraventricular immunoglobulin, virus recovery from ventricular cerebrospinal fluid stopped soon after the start of treatment, but recurred within weeks of it stopping. The period of viral eradication was no greater when immunoglobulin and interferon were used in combination than when immunoglobulin was used alone.
The failure of these two forms of treatment in this patient accentuate the need for the development of further antiviral agents effective against the picornavirus group of agents before successful treatment of this type of infection can be assured in patients with hypogammaglobulinaema. Some such agents may become available: benzimidazole derivatives have been shown to inhibit multiplication of picornaviruses, and more recently an arildone derivative, WIN 51711, has been shown to have antipicornavirus activity. 22 It is possible that such agents may also have a degree of synergy with interferon (D Tyrell, personal communication). In the absence of effective antiviral chemotherapy, hypogammaglobulinaemic patients who do not respond to intraventricular immunoglobulin treatment may deserve consideration as candidates for bone marrow transplantation in an attempt to provide an adequate immune response to the infecting agent.
